Metabolic dysfunction-associated steatohepatitis is associated with increased all-cause mortality

Zhao Li; Rui Song; Yingzhi Zhang; Jiahe Tan; Zhiwei Chen

doi:10.1101/2024.06.28.24309687

Abstract

Background Recently, the new nomenclature metabolic dysfunction-associated steatohepatitis (MASH) was proposed to supersede non-alcoholic steatohepatitis (NASH). To optimize the management of these patients, it is crucial to comprehend the similarities and differences between individuals with NASH and MASH.

Methods We analyzed data from 13,846 participants in the third National Health and Nutrition Examination Surveys, along with their linked mortality through 2019. NASH and MASH were defined based on respective criteria. Survey-weight adjusted multivariable Cox proportional model was used to examine mortality.

Results The overall prevalence of steatohepatitis, NASH and MASH was 5.7% (n=788), 4.1% (n=564) and 5.5% (n=763), respectively. Most individuals with NASH (96.8%) could be categorized as MASH, but only 69.7% individuals with MASH qualified as NASH. During a median follow-up of 27 years, individuals with MASH exhibited a 53% higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.53, 95% CI 1.24-1.89). But individuals with NASH didn’t show an association with all-cause mortality after adjustment for metabolic risk factors (aHR 1.14, 95% CI 0.91-1.44). Notably, individuals who met the criteria for MASH but not NASH (NASH(-)/MASH(+)) had a higher risk of all-cause mortality (aHR 2.47, 95% CI 1.71-3.57) compared to those with NASH(+)/MASH(+) (aHR 1.22, 95% CI 0.97-1.55). Moreover, advanced fibrosis was only associated with an increased risk of all-cause mortality in individuals with MASH, not NASH.

Conclusions MASH, rather than NASH, was associated with an elevated risk of all-cause mortality after adjusting for metabolic risk factors. Well-designed prospective studies are needed to assess and validate our findings.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

this work was supported by the Science and technology research project of Chongqing Education Commission (KJZD-K202300404), Remarkable Innovation-Clinical Research Project and the DengFeng Program of the Second Affiliated Hospital of Chongqing Medical University, and The First batch of key Disciplines on Public Health in Chongqing, Health Commission of Chongqing, China.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://wwwn.cdc.gov/nchs/nhanes/Nhanes3/Default.aspx

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Author’s email address: Zhao Li: 1546866602{at}qq.com, Rui Song: sr202099{at}163.com, Yingzhi Zhang: zhangyingzhi217{at}163.com, Jiahe Tan: tanjiahe1995{at}163.com, Zhiwei Chen: zhiwei_chen{at}cqmu.edu.cn

Data Availability Statement

All data produced in the present study are available upon reasonable request to the authors.

Abbreviations

ALT: alanine aminotransferase
AST: aspartate aminotransferase
BMI: body mass index
CI: confidential intervals
FIB-4: fibrosis-4
HR: hazard ratio
HEI: healthy eating index
MASH: metabolic dysfunction-associated steatohepatitis
MASLD: metabolic dysfunction associated steatotic liver disease
NAFLD: nonalcoholic fatty liver disease
NASH: nonalcoholic steatohepatitis
NHANES III: Third National Health and Nutrition Examination Survey
NFS: NAFLD fibrosis score
PIR: poverty impact ratio.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.